Drugs / SmofKabiven extra Nitrogen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05257031 | Feb → Sep 2022 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03992716 | Nov 2019 → Mar 2020 | — | Fresenius Kabi | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SmofKabiven extra Nitrogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05257031 ↗ |
| Modality | Other / unclassified | “sterile, hypertonic emulsion for parenteral nutrition” NCT03992716 ↗ |
| Route | Other | “for parenteral nutrition” NCT03992716 ↗ |